Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 1:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 88 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Post-Lung Transplantation Clear all
Recruiting Phase 3 Interventional

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

NCT06615050
View directory record Official record
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Tacrolimus (Tac), Methotrexate (MTX), Ruxolitinib (Rux), Cyclophosphamide, Mycophenolate mofetil (MMF)
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
30
States / cities
Palo Alto, California • San Francisco, California • Miami, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 1, 2026, 1:55 AM EDT
Completed No phase listed Observational

Factors Predicting Success in Lung Transplant Recipients Who Have Undergone Intensive Post-operative Rehabilitation

NCT03299504
View directory record Official record
Conditions
Lung Transplant
Interventions
Exercise
Other
Lead sponsor
Indiana University Health Methodist Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 24, 2018 · Synced Oct 1, 2026, 1:55 AM EDT
Completed Not applicable Interventional

Comparing Methods for Tracking Health Information at Home After Lung Transplant

NCT00818025
View directory record Official record
Conditions
Lung Disease
Interventions
Pocket PATH (Personal Assistant for Tracking Health)
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 1, 2026, 1:55 AM EDT
Recruiting Not applicable Interventional

A Study of Latin Dance for Post- Lung Transplant

NCT05924113
View directory record Official record
Conditions
Lung Transplant, Well-Being, Psychological
Interventions
Latin Dance
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 1, 2026, 1:55 AM EDT
Completed No phase listed Observational

GI Reflux in Lung Transplant and Its Relationship to Chronic Rejection

NCT00455078
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
esophagogastroduodenoscopy, Standard GER questionnaire (RDQ), Scintigraphic evaluation of solid gastric emptying, Twenty-four hour ambulatory pH testing, Esophageal manometry testing
Procedure · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 1, 2026, 1:55 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

NCT05327023
View directory record Official record
Conditions
Hematologic Neoplasms
Interventions
donor lymphocyte infusion, Cyclophosphamide, Busulfan, Mycophenolate mofetil, Fludarabine, Sirolimus
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 1, 2026, 1:55 AM EDT
Completed No phase listed Observational

Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation

NCT01206309
View directory record Official record
Conditions
Graft vs Host Disease, Cutaneous Sclerosis, Bronchiolitis Obliterans
Interventions
Not listed
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
911 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
14
States / cities
Scottsdale, Arizona • Stanford, California • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 1, 2026, 1:55 AM EDT
Terminated Phase 2 Interventional Results available

Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)

NCT00675441
View directory record Official record
Conditions
Graft-versus-Host Disease
Interventions
Lenalidomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Oct 1, 2026, 1:55 AM EDT
Withdrawn No phase listed Observational

Evaluation of Tolsura When Used as Prophylaxis After Lung Transplantation

NCT04652050
View directory record Official record
Conditions
Lung Transplant Infection
Interventions
Tolsura
Drug
Lead sponsor
Hong Nguyen
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 1, 2026, 1:55 AM EDT
Recruiting Not applicable Interventional

Intercostal Cryoanalgesia in Double Lung Transplant Recipients

NCT07281118
View directory record Official record
Conditions
Post-operative Pain Management
Interventions
Atricure CryoSPHERE MAX Probe
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • Waco, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 1, 2026, 1:55 AM EDT
Withdrawn Phase 2 Interventional

Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias

NCT05509582
View directory record Official record
Conditions
Immune Mediated Anemia, Immune Mediated Thrombocytopenia, Chronic GVHD
Interventions
fostamatinib
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 1, 2026, 1:55 AM EDT
Not listed Phase 1 Interventional

AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT00324597
View directory record Official record
Conditions
Lung Cancer, Lymphoma, Lymphoproliferative Disorder, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
gemcitabine hydrochloride, motesanib diphosphate, pharmacological study
Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 1, 2026, 1:55 AM EDT
Terminated Phase 2 Interventional

Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant

NCT04908735
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplant (HSCT), Bronchiolitis Obliterans (BO)
Interventions
Ruxolitinib
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Minneapolis, Minnesota • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 1, 2026, 1:55 AM EDT
Active, not recruiting Not applicable Interventional

Inspiratory Muscle Training Immediately After Lung Transplantation

NCT05309551
View directory record Official record
Conditions
Lung Transplantation, Chronic Lung Disease, Muscle Weakness, Rehabilitation
Interventions
IMT- Intervention group, IMT- Placebo group
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 1, 2026, 1:55 AM EDT
Terminated Phase 4 Interventional

Voriconazole as Prophylactic Therapy in Lung Transplant Recipients

NCT00455364
View directory record Official record
Conditions
Infection
Interventions
Voriconazole
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Oct 1, 2026, 1:55 AM EDT
Completed Phase 2 Interventional Results available

COVID Protection After Transplant-Immunosuppression Reduction

NCT05077254
View directory record Official record
Conditions
Kidney Transplant Recipients, Liver Transplant Recipients
Interventions
Pfizer-BioNTech COVID-19 Vaccine 2023-2024, Moderna COVID-19 Vaccine 2023-2024, SOC IS Regimen, SOC IS Reduction
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
15
States / cities
San Diego, California • San Francisco, California • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 1, 2026, 1:55 AM EDT
Completed Not applicable Interventional

Live Music Therapy to Reduce Anxiety, Pain and Improve Sleep in Post-Operative Lung Transplant Patients: a Pilot Study

NCT04975607
View directory record Official record
Conditions
Lung Transplant; Complications
Interventions
Music Therapy
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Not listed
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 1, 2026, 1:55 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

NCT03112603
View directory record Official record
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
38
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 1, 2026, 1:55 AM EDT
Terminated Phase 4 Interventional Results available

Comparison of Insulin Therapy in Treating Post-Transplant Diabetes

NCT01963728
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Insulin, Isophane, insulin glargine
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 1, 2026, 1:55 AM EDT
Not listed No phase listed Observational

HR-EGG in Medically Refractory Gastroparesis

NCT05789511
View directory record Official record
Conditions
Gastroparesis, Lung Transplant; Complications
Interventions
High Resolution Electrogastography
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Houston, Texas • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 31, 2023 · Synced Oct 1, 2026, 1:55 AM EDT
Completed Not applicable Interventional Results available

Improving Lung Transplant Outcomes With Coping Skills and Physical Activity

NCT04093869
View directory record Official record
Conditions
Post-Lung Transplantation
Interventions
Coping Skills Training combined with Exercise (CSTEX), Standard of Care plus Education (SOC-ED)
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 1, 2026, 1:55 AM EDT
Completed Phase 2 Interventional Results available

Bandage Lenses in Treating Patients With Ocular Graft-Versus-Host Disease

NCT01616056
View directory record Official record
Conditions
Graft Versus Host Disease, Ophthalmologic Complications
Interventions
graft versus host disease prophylaxis/therapy, questionnaire administration, optical coherence tomography
Biological · Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Oct 1, 2026, 1:55 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Lung Ultrasound Artefact Analysis for Exclusion of Acute Rejection in Lung Transplant Recipients

NCT04582279
View directory record Official record
Conditions
Post-Lung Transplantation Bronchiectasis
Interventions
Lung ultrasound
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 1, 2026, 1:55 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant

NCT01559844
View directory record Official record
Conditions
Hepatitis C, Hepatocellular Carcinoma
Interventions
Sofosbuvir, Ribavirin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Oct 1, 2026, 1:55 AM EDT